Company intelligence / Profile preview

Pilatus Biosciences

Epalinges, Vaud, Switzerlandpilatusbio.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Pilatus Biosciences is a preclinical-stage biotech company pioneering immunometabolic therapies. Its lead asset, PLT012—a humanized anti-CD36 antibody—has demonstrated strong preclinical efficacy in liver and colorectal cancers. The molecule received FDA Orphan Drug Designation in late 2024 for liver and intrahepatic bile duct cancers. The company plans to submit its first US IND application and begin clinical trials in 2025.

Therapeutic areas: Oncology
Modalities: First-in-class antibodiesBifunctional proteins (biologics)
Industry: Biotech

Drug pipeline

4 assets

PLT012

3 more assets in the full pipeline.

Request access →

Partnerships

Ludwig Institute for Cancer ResearchUniversity of LausanneCancer Research Institute (New York)

Beyond the preview

Go deeper on Pilatus Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pilatus Biosciences.

Explore the full profile